An overview of the mTOR pathway as a target in cancer therapy

Targeting mTOR for the treatment of AML. New agents and new directions.

(2015) Jessica K. Altman et al.   Oncotarget

Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies

(2011) M. Gupta et al.   BLOOD

A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas

(2011) Scott Okuno et al.   CANCER

Activation of mTORC2 by Association with the Ribosome

(2011) Vittoria Zinzalla et al.   CELL

High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1

(2011) Paige Yellen et al.   CELL CYCLE

Impact ofBCR-ABLmutations on patients with chronic myeloid leukemia

(2011) Andreas Hochhaus et al.   CELL CYCLE

Dual mTORC2/mTORC1 Targeting Results in Potent Suppressive Effects on Acute Myeloid Leukemia (AML) Progenitors

(2011) J. K. Altman et al.   CLINICAL CANCER RESEARCH

Molecular Pathways: BCR-ABL

(2011) D. Cilloni et al.   CLINICAL CANCER RESEARCH

mTOR signaling in disease

(2011) Eva Dazert et al.   CURRENT OPINION IN CELL BIOLOGY

Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies

(2011) Nushmia Z. Khokhar et al.   CURRENT OPINION IN ONCOLOGY

CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies

(2011) Jorge J Castillo et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

The role of LKB1 in lung cancer

(2011) Montse Sanchez-Cespedes   Familial Cancer

Future Directions in Renal Cell Carcinoma: 2011 and Beyond

(2011) Daniel C. Cho et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

mTOR Inhibitors in Advanced Renal Cell Carcinoma

(2011) Martin H. Voss et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Phosphatidylinositol 3-Kinase and Antiestrogen Resistance in Breast Cancer

(2011) Todd W. Miller et al.   JOURNAL OF CLINICAL ONCOLOGY

Front-Line and Salvage Therapies With Tyrosine Kinase Inhibitors and Other Treatments in Chronic Myeloid Leukemia

(2011) Jorge Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas

(2011) Sant P. Chawla et al.   JOURNAL OF CLINICAL ONCOLOGY

Regulation of mammalian target of rapamycin and mitogen activated protein kinase pathways by BCR–ABL

(2011) Amanda J. Redig et al.   LEUKEMIA & LYMPHOMA

New developments in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia

(2011) Amber Fullmer et al.   LEUKEMIA & LYMPHOMA

Mechanisms of resistance to BCR–ABL kinase inhibitors

(2011) Joana M. Diamond et al.   LEUKEMIA & LYMPHOMA

Rapamycin passes the torch: a new generation of mTOR inhibitors

(2011) Don Benjamin et al.   NATURE REVIEWS DRUG DISCOVERY

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

(2011) James C. Yao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors

(2011) Y. Jiao et al.   SCIENCE

New molecular targets in mantle cell lymphoma

(2011) Samir Parekh et al.   SEMINARS IN CANCER BIOLOGY

Mechanisms of mTOR inhibitor resistance in cancer therapy

(2011) Jennifer S. Carew et al.   Targeted Oncology

Induction of autophagy by dual mTORC1-mTORC2 inhibition in BCR-ABL-expressing leukemic cells

(2010) Eliza Vakana et al.   Autophagy

The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma

(2010) D. C. Cho et al.   CLINICAL CANCER RESEARCH

Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia

(2010) D Bixby et al.   LEUKEMIA

mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3-mutated acute myeloid leukemia cells

(2010) Weina Chen et al.   Molecular Cancer

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

(2010) Matthew R Janes et al.   NATURE MEDICINE

Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer

(2010) T Sato et al.   ONCOGENE

Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells

(2010) Nathalie Carayol et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Dual Inhibition of Class IA Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin as a New Therapeutic Option for T-Cell Acute Lymphoblastic Leukemia

(2009) F. Chiarini et al.   CANCER RESEARCH

An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1

(2009) Carson C. Thoreen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

(2009) Georg Hess et al.   JOURNAL OF CLINICAL ONCOLOGY

Pancreatic Endocrine Tumors: Expression Profiling Evidences a Role for AKT-mTOR Pathway

(2009) Edoardo Missiaglia et al.   JOURNAL OF CLINICAL ONCOLOGY

The PTEN/PI3K/AKT Signalling Pathway in Cancer, Therapeutic Implications

(2008) Amancio Carnero et al.   CURRENT CANCER DRUG TARGETS

Exploiting the mammalian target of rapamycin pathway in hematologic malignancies

(2008) Jessica K Altman et al.   CURRENT OPINION IN HEMATOLOGY

Differential Dependence of Hypoxia-inducible Factors 1α and 2α on mTORC1 and mTORC2

(2008) Alfredo Toschi et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells

(2008) Michael G. Kharas et al.   JOURNAL OF CLINICAL INVESTIGATION

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

(2008) Robert J Motzer et al.   LANCET

The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML

(2008) K Kojima et al.   LEUKEMIA

PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML

(2008) S Park et al.   LEUKEMIA

Lack of antileukemic activity of rapamycin in elderly patients with acute myeloid leukemia evolving from a myelodysplastic syndrome

(2008) Fernando Callera et al.   LEUKEMIA RESEARCH

Regulation of mTORC1 and mTORC2 Complex Assembly by Phosphatidic Acid: Competition with Rapamycin

(2008) A. Toschi et al.   MOLECULAR AND CELLULAR BIOLOGY

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

(2008) S.-M. Maira et al.   MOLECULAR CANCER THERAPEUTICS

PI3K pathway alterations in cancer: variations on a theme

(2008) T L Yuan et al.   ONCOGENE